Activity Dates: 01/09/2019 - 07/09/2019
The Psychiatric Pharmacotherapy Review Course (Review Course) is designed for two primary audiences:
NOTE: The Psychiatric Pharmacotherapy Review Course is a two-year product released at the start of even years (2018, 2020, 2022...). Given this revision cycle, individuals cannot repeat the current edition of the Review Course for BCPP Recertification or ACPE credit.
Whether a certification candidate or a currently certified individual, the goal of the Review Course is to assist the practitioner in developing and maintaining contemporary knowledge and skills at the psychiatric pharmacy specialty level. The Review Course is not designed to develop more in-depth "subspecialty" knowledge. Course content is structured to provide a comprehensive review of the three psychiatric pharmacy domains specified by the Specialty Council in the current edition of the BPS Candidate's Guide. Inclusion of the Review Course as part of the recertification program is critical in ensuring the BCPP has systematically reviewed and assessed his/her core knowledge in the psychiatric specialty practice. This course is a knowledge-based educational program designed for pharmacists to acquire factual knowledge.
The course includes:
Consider the BCPP Prep Series for additional study aids. It provides recorded webinar presentations that are structured around this review course. The webinars feature case-based self-assessment questions with feedback.
To satisfactorily complete the recertification programming and receive 20 hours of BCPP Recertification and ACPE credit, candidates must meet the following requirements:
You will proceed through the following steps to satisfactorily complete this course:
Participants successfully passing the required examination will obtain both ACPE and BCPP recertification credit. Credit is awarded in the calendar year the assessment is completed. ACPE credit is reported through CPE Monitor within days of examination submission, while BCPP recertification credit is reported to BPS within 6 weeks after the examination deadline.
AAPP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access AAPP course materials online, you will need:
AAPP web sites no longer fully support Microsoft Internet Explorer or Windows 8.1 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Jolene Bostwick, PharmD, BCPS, BCPP
Associate Chair & Clinical Associate Professor, Department of Clinical Pharmacy No Relevant Financial Relationships to Disclose My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: psychotropics used to treat psychiatric comorbidities. May be others; however, information will be based on published literature and will be clearly stated the medications are off-label |
Steven Burghart, RPh, DPh, MBA, BCPP
Clinical Pharmacist Psychiatry No Relevant Financial Relationships to Disclose |
Joshua Caballero, PharmD, BCPP, FCCP
Professor No Relevant Financial Relationships to Disclose Presentation will include discussion of off-label, experimental, and/or investigational use of drugs or devices: psychotropics used to treat psychiatric comorbidities. May be others; however, information will be based on published literature and will be clearly stated the medications are off-label |
Ryan Carnahan, PharmD, MS, BCPP
Associate Professor No Relevant Financial Relationships to Disclose |
Norman Carroll, BSPharm, MS, PhD
Professor No Relevant Financial Relationships to Disclose |
Megan Ehret, PharmD, MS, BCPP
Associate Professor
University of Maryland
Baltimore, MD External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Barrons PCAT Review Book Evaluator, PSAP Book Chapter Author |
Lisa W. Goldstone, PharmD, MS, BCPS, BCPP
Associate Professor of Clinical Pharmacy No Relevant Financial Relationships to Disclose |
Cynthia A. Gutierrez, PharmD, MS, BCPP
Clinical Pharmacy Program Manager, Mental Health No Relevant Financial Relationships to Disclose Presentation will include discussion of off-label, experimental, and/or investigational use of drugs or devices: Lithium, triiodothyronine, buspirone, risperidone as augmentation strategies for depression |
Calleen Lavinghousez, PharmD, BCPS, BCPP
VISN 7 Academic Detailing Pharmacist, Mental Health Clinical Pharmacy Specialist No Relevant Financial Relationships to Disclose Presentation will include discussion of off-label, experimental, and/or investigational use of drugs or devices: gabapentin |
Megan Maroney, PharmD, BCPP
Clinical Associate Professor No Relevant Financial Relationships to Disclose External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Janssen Connect (division of Janssen Pharmaceuticals); Speakers Bureau: Otsuka-Lundbeck EXCEL Speaker's Bureau |
Sandra Mullen, PharmD, BCPP
Clinical Pharmacy Specialist-Psychiatry Other Financial or Material Support: CVS/pharmacy employee stock |
Carol Ott, PharmD, BCPP
Clinical Professor of Pharmacy Practice Non-Financial Interests: Indiana Medicaid Drug Utilization Review (DUR) Board, Indiana Medicaid Mental Health Quality Advisory Committee (MHQAC), Primary Care Psychiatry Foundation Board of Directors, NAMI West Central Board of Directors |
Chris Paxos, PharmD, BCPP, BCPS, BCGP
Pharmacotherapy Specialist No Relevant Financial Relationships to Disclose |
Kimberly Tallian, PharmD, APH, BCPP, FASHP, FCCP, FCSHP
Psychiatry Pharmacy Specialist No Relevant Financial Relationships to Disclose |
Traci Turner, PharmD, BCPP
Clinical Pharmacy Specialist No Relevant Financial Relationships to Disclose |
Hours | Topic |
---|---|
2.0 hours |
Anxiety and Anxiety-Related Disorders
# 0284-0000-16-030-H01-P (Knowledge)
|
2.0 hours |
Biostatistics and Research Design in Psychiatry
# 0284-0000-16-032-H04-P (Knowledge)
|
1.5 hours |
Bipolar Disorder
# 0284-0000-16-031-H01-P (Knowledge)
|
1.5 hours |
Depression
# 0284-0000-16-033-H01-P (Knowledge)
|
1.5 hours |
Economic and Outcome Studies in Psychiatry
# 0284-0000-16-034-H04-P (Knowledge)
|
1.0 hour |
Neurocognitive Disorders
# 0284-0000-16-037-H01-P (Knowledge)
|
1.0 hour |
Neurodevelopmental, Disruptive, Impulse-Control and Conduct Disorders
# 0284-0000-16-038-H01-P (Knowledge)
|
2.0 hours |
Neurologic Disorders
# 0284-0000-16-035-H01-P (Knowledge)
|
1.0 hour |
Personality Disorders and Eating Disorders
# 0284-0000-16-036-H01-P (Knowledge)
|
1.5 hours |
Regulatory Issues in Pharmacy Practice
# 0284-0000-16-039-H04-P (Knowledge)
|
2.0 hours |
Schizophrenia Spectrum and Other Psychotic Disorders
# 0284-0000-16-040-H01-P (Knowledge)
|
1.5 hours |
Sleep-Wake Disorders
# 0284-0000-16-041-H01-P (Knowledge)
|
1.5 hours |
Substance-Related Disorders
# 0284-0000-16-042-H01-P (Knowledge)
|
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The 2018-2019 Psychiatric Pharmacotherapy Review Course is a knowledge-based course and will provide 20 hours (2.0 CEUs) of continuing education credit.
Additionally, the 2018-2019 Psychiatric Pharmacotherapy Review Course will provide 20 hours of BCPP Recertification credit. BCPP Recertification credit is earned and reported within the year the assessment is successfully completed. This course is also accessible in CPNP University on a per module basis.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
2018-2019 Editorial Board
Benjamin Chavez, PharmD, BCPP, BCACP Associate Professor University of Colorado Skaggs School of Pharmacy Aurora, CO External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: ACSAP Book Chapter Author Non-Financial Interests: Board of Directors of CPNP |
Megan J. Ehret, PharmD, MS, BCPP |
Clayton D. English, PharmD, BCPP, BCPS |
Rex S. Lott, PharmD, BCPP Professor Emeritus of Pharmacy Practice Idaho State University - College of Pharmacy Meridian, ID No Relevant Financial Relationships to Disclose |
Carol A. Ott, PharmD, BCPP |
Chris Paxos, PharmD, BCPP, BCPS, BCGP Pharmacotherapy Specialist Cleveland Clinic Akron General Akron, OH No Relevant Financial Relationships to Disclose |
Stephanie V. Phan, PharmD, BCPP |
Todd J. Woodard, PharmD, BCPP, BCPS, BCGP, CPE Manager, Clinical Pharmacy Services Peach State Health Plan Atlanta, GA Adjunct Clinical Assistant Professor of Pharmacy Practice Philadelphia College of Osteopathic Medicine School of Pharmacy Suwanee, GA No Relevant Financial Relationships to Disclose |
Jennifer L. Zacher, PharmD, BCPP Assistant Chief Consultant VA Pharmacy Benefits Management Service Hines, IL No Relevant Financial Relationships to Disclose |
2018-2019 Peer Reviewers
Katie Adams, PharmD, BCPP, BCPS |
Cassandra Clement, PharmD, BCPS, BCPP Mental Health Clinical Pharmacy Specialist Orlando VA Medical Center Orlando, FL |
Nicole Cupples, PharmD, BCPP, BCPS Clinical Pharmacist South Texas Veterans Healthcare System San Antonio, TX No Relevant Financial Relationships to Disclose |
Kathryn DeMent, BCPS, BCPP Clinical Pharmacist Eastern Kansas VAMC Topeka, KS No Relevant Financial Relationships to Disclose |
Lauren Diefenderfer, PharmD, BCPP Clinical Pharmacist Center for Behavioral Medicine Kansas City, MO |
Amie Jo Digatono, PharmD, BCPP Pharmacist Mercy Hospital - Unity Campus Fridley, MN No Relevant Financial Relationships to Disclose |
Courtney Eatmon, PharmD, BCPP Clinical Pharmacist Veterans Affairs Medical Center Lexington, KY External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: BPS specialty council as a non-specialist member of pharmacotherapy board |
Jessica Goren, PharmD, BCPP |
Tonya Gross, PharmD, BCPP Clinical Pharmacist Avera Behavioral Health Center Sioux Falls , SD No Relevant Financial Relationships to Disclose |
Beth Hall, PharmD, BCPP Director of Pharmacy Fulton State Hospital Fulton, MO |
Jessica Ho, PharmD, BCPP, BCPS Clinical Pharmacy Specialist, Psychiatry Kaiser Permanente of the Mid-Atlantic States Burke, VA No Relevant Financial Relationships to Disclose |
Cherry Jackson, PharmD, BCPP, FASHP Professor of Pharmacy, Auburn University; Professor of Medicine, University of Alabama, Birmingham Auburn University Harrison School of Pharmacy, University of Alabama, Birmingham, School of Medicine Birmingham, AL Non-Financial Interests: CPNP, ASHP, AlSHP |
Ismar Karadzic, PharmD, BCPP Regional Director of Pharmacy Eastern Missouri Psychiatric Hospital System Regional Director of Pharmacy St. Louis, MO |
Katherine Koller, PharmD, BCPP Psychiatric Clinical Pharmacy Specialist Battle Creek VA Medical Center Battle Creek, MI |
Marketa Marvanova, PharmD, BCGP, BCPP, PhD |
Lindsey N. Miller, PharmD, BCPP |
Jason Noel, PharmD, BCPP Faculty University of Maryland Baltimore, MD No Relevant Financial Relationships to Disclose |
William Olsufka, PharmD, BCPP Assistant Professor Touro College of Pharmacy New York, NY No Relevant Financial Relationships to Disclose |
Mamta Parikh, PharmD, BCPS, BCPP Assistant Professor, Clinical and Administrative Sciences School of Pharmacy Notre Dame of Maryland University Baltimore , MD Employment: Notre Dame of Maryland University School of Pharmacy |
Alyssa Peckham, PharmD, BCPP Assistant Professor of Pharmacy Practice Midwestern University Glendale, AZ |
Talia Puzantian, PharmD, BCPP Associate Professor Keck Graduate Institute Claremont, CA No Relevant Financial Relationships to Disclose |
Shannon Saldana, PharmD, MS, BCPP Pharmacy Clinical Specialist, Psychiatry Primary Children's Hospital Sandy, UT |
Thomas Smith, PharmD, BCPP Assistant Professor of Pharmacy Practice Manchester College of Pharmacy Fort Wayne, IN |
Gita Soltani, PharmD, BCCP, BCPS Clinical Pharmacist Florida State Hospital Chattahoochee, FL |
Katy Tomisser, PharmD, BCPP Director of Pharmacy Western State Hospital Pharmacy Lakewood, WA |
Gabriela Williams, PharmD, BCPS, BCPP Clinical Pharmacy Specialist, Psychiatry Eskenazi Health Indianapolis, IN |
All relevant relationships have been mitigated.
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information and disclosures). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Generalized anxiety disorder: Benzodiazepines, pregabalin, tiagabine, second generation antipsychotics (olanzapine, risperidone, quetiapine, aripiprazole), trazodone, imipramine, bupropion, escitalopram, vortioxetine, vilazodone, kava, valerian, lavender oil, divalproex/valproate, propranolol Panic disorder: duloxetine, tricyclic antidepressants (clomipramine, imipramine), mirtazapine, phenelzine, tranylcypromine, benzodiazepines, bupropion, divalproex, gabapentin, levetiracetam, milnacipran, olanzapine, quetiapine, risperidone, aripiprazole, pindolol, tiagabine, vigabatrin, buspirone, trazodone, propranolol Post-traumatic stress disorder: SSRIs (fluoxetine, paroxetine, citalopram, fluvoxamine, escitalopram), venlafaxine, tricyclic antidepressants including imipramine and amitriptyline, mirtazapine, phenelzine, nefazodone, anticonvulsants (carbamazepine, lamotrigine, topiramate, valproic acid/divalproex sodium, gabapentin, levetiracetam, pregabalin), second generation antipsychotics, adrenergic inhibitors (prazosin, clonidine), second generation antipsychotics (risperidone, olanzapine, aripiprazole, quetiapine), eszopiclone, buspirone, memantine, trazodone, clonidine Obsessive-compulsive disorder: escitalopram, venlafaxine, mirtazapine, memantine, topiramate, antipsychotics (haloperidol and second generation antipsychotics including aripiprazole, risperidone, quetiapine, olanzapine, ziprasidone), tramadol, phenelzine, tranylcypromine, celecoxib, granisetron, ondansetron, IV ketamine, N-acetylcysteine, pindolol, prebablin, riluzole, clonazepam, clonidine, desipramine, lithium, buspirone, natural products including d-cycloserine Social anxiety disorder: clonazepam, citalopram, fluoxetine, escitalopram, paroxetine, fluvoxamine, venlafaxine, imipramine, clomipramine, buspirone, gabapentin, pregabalin, propranolol, atenolol, olanzapine, risperidone, aripiprazole, quetiapine, phenelzine, atomoxetine, bupropion, duloxetine, mirtazapine, divalproex, tiagabine, topiramate, levetiracetam, selegiline Separation anxiety disorder: selective serotonin reuptake inhibitors, venlafaxine, duloxetine, imipramine, desipramine, benzodiazepines My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: (possibly) haloperidol (acute mania), clozapine (refractory bipolar disorder) My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Lithium, triiodothyronine, buspirone, risperidone as augmentation strategies for depression My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: psychotropics used to treat psychiatric comorbidities. May be others; however, information will be based on published literature and will be clearly stated the medications are off-label My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: bupropion, imipramine, desipramine, and notriptyline, immediate-release alpha-agonists for ADHD. Stimulants and second generation antipsychotics for ODD/CD. Anitdepressants, mood stabilizers, alpha agonists for autism spectrum disorders My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: antihistamines, trazodone, mirtazapine, amitriptyline, gabapentin, tiagabine, quetiapine, olanzapine, melatonin, tryptophan, german chamomile, kava kava and valerian for insomnia, antidepressants and stimulants for narcolepsy and obstructive sleep apnea, methylxanthenes, estrogen, nasal decongestants, mirtazapine, paroxetine, xylometazoline, pantoprazole, zolpidem, eszopiclone and acetazolamide for obstructive sleep apnea, melatonin and vitamin B12 for circadian rhythm disorders, carbidopa/levodopa, cabergoline, pregabalin, iron, clonazepam, gabapentin, carbamazepine, clonidine, lisuride, amantadine, valproic acid, oxcarbazepine, rifaximin, botulinum neurotoxin, bupropion, selenium, transcranial magnetic stimulation, near-infrared spectroscopy, valerian, vitamin C and E and opioids for restless legs syndrome My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: gabapentin
This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), or are currently investigational.
In accordance with the Food and Drug Administration (FDA), it is disclosed that there is the potential for discussions concerning off-label uses of a commercial product/devices during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose significant relationships (and any known relationships of their spouse/partner) with commercial companies whose products or services are discussed in this activity. Significant relationships include receiving from a commercial company research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.